- In October 2013, Dr. Xiaoliang Cheng, founder of Qlife, received the R&D 100 Awards as one of the inventors of Qchip, the world's leading high-throughput mass spectrometry chip technology
Jiangsu Qlife Medical Technology Group Co., LTD. ("Qlife "") is a high-tech company in the field of precision medicine. Centered on mass spectrometry technology and driven by multi-omics research, we pioneer the innovation in developing diagnostics for the healthcare industry. We provide the leading total solution of clinical mass spectrometry, including omics research, mass spectrometry instruments, IVD reagents, and ICL services. We are the leader of multi-omics research translation and clinical mass spectrometry technology development for precision medicine in China.
As a technology driven company, Qlife has developed an internationally leading research platform of proteomics and metabolomics that can support untargeted and targeted clinical omics research as well as new biomarker discovery, and verification and translation of innovative clinical applications. At present, the company offers the testing of more than 500 clinical mass spectrometry analytes, covering maternal and neonatal health, endocrinological, cardiovascular, tumor, neurological, and Therapeutics Drug Monitoring, including numerous original precision omics assays, leading the development of China's clinical mass spectrometry market.
Qlife has established subsidiaries or branches in Nanjing, Shanghai, Beijing, Wuhan, Hangzhou, Fuzhou, Xi'an and other places, including R&D centers, medical device factories and independent clinical laboratories, and has built a nationwide sales and service network. With excellent technical strength and robust service system, Qlife has established in-depth cooperation with dozens of benchmark hospitals in China, and its products and services have been widely acclaimed through verification of industry KOLs.
The expertise and focus of Qlife has been widely recognized by the investment community, and has received multiple rounds of investments by IDG Capital, Centurium Capital, Cowin Capital, Yang Zi Investment Group and other famous venture capital investors.
Hoping to let precision medicine benefit everyone, Qlife will continue to focus on applying multi-omics technology to precision medicine, and is committed to developing the clinical mass spectrometry industry, promoting innovation, serving precision medicine, benefiting human health, and improving quality of life. "